Private Advisor Group LLC Acquires 3,458 Shares of Codexis, Inc. (NASDAQ:CDXS)

Private Advisor Group LLC boosted its position in shares of Codexis, Inc. (NASDAQ:CDXS) by 1.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 278,699 shares of the biotechnology company’s stock after buying an additional 3,458 shares during the period. Private Advisor Group LLC’s holdings in Codexis were worth $858,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Algert Global LLC boosted its position in shares of Codexis by 17.1% in the 2nd quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 6,069 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Codexis by 82.4% in the 2nd quarter. AQR Capital Management LLC now owns 237,272 shares of the biotechnology company’s stock valued at $736,000 after purchasing an additional 107,205 shares in the last quarter. Squarepoint Ops LLC increased its stake in shares of Codexis by 113.8% in the 2nd quarter. Squarepoint Ops LLC now owns 74,531 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 39,664 shares in the last quarter. Marshall Wace LLP purchased a new stake in Codexis during the 2nd quarter worth approximately $89,000. Finally, Dimensional Fund Advisors LP increased its stake in Codexis by 34.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 340,762 shares of the biotechnology company’s stock worth $1,056,000 after buying an additional 87,457 shares in the last quarter. 78.54% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Codexis news, major shareholder Opaleye Management Inc. acquired 1,055,000 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was acquired at an average cost of $3.01 per share, with a total value of $3,175,550.00. Following the purchase, the insider now directly owns 8,390,000 shares in the company, valued at approximately $25,253,900. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. In the last three months, insiders purchased 1,166,000 shares of company stock worth $3,514,910. Company insiders own 2.10% of the company’s stock.

Codexis Stock Performance

Shares of CDXS stock opened at $3.50 on Friday. Codexis, Inc. has a 1 year low of $1.51 and a 1 year high of $4.91. The firm has a market cap of $248.24 million, a price-to-earnings ratio of -4.02 and a beta of 2.07. The stock’s 50-day moving average is $3.05 and its two-hundred day moving average is $3.15. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.92 and a current ratio of 2.99.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.06). The firm had revenue of $7.98 million during the quarter, compared to analyst estimates of $7.64 million. Codexis had a negative net margin of 125.41% and a negative return on equity of 64.06%. During the same quarter in the previous year, the business earned ($0.17) EPS. Analysts predict that Codexis, Inc. will post -0.75 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on CDXS shares. Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price target on shares of Codexis in a research report on Friday, September 20th. Benchmark lowered Codexis from a “buy” rating to a “hold” rating in a research report on Monday, August 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Codexis presently has an average rating of “Hold” and a consensus target price of $8.75.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.